Menopausal hormone therapy and breast cancer risk: the cardiological point of view

Affiliations

Comment

Susanna Sciomer et al. J Cardiovasc Med (Hagerstown). 2020 Aug.

. 2020 Aug;21(8):538-539.

doi: 10.2459/JCM.0000000000000969.

¹ Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, University of Rome 'Sapienza', Policlinico Umberto I Hospital, Rome, Italy.

No abstract available

Comment on

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
Collaborative Group on Hormonal Factors in Breast Cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 2019 Sep 28;394(10204):1159-1168. doi: 10.1016/S0140-6736(19)31709-X. Epub 2019 Aug 29. Lancet. 2019. PMID: 31474332 Free PMC article.

1. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394:1159–1168.
1. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37:3232–3245.
1. Kotsopoulos J. Menopausal hormones: definitive evidence for breast cancer. Lancet 2019; 394:1116–1118.
1. Muka T, Vargas KG, Jaspers L, Wen KX, Dhana K, Vitezova A, et al. Estrogen receptor β actions in the female cardiovascular system: a systematic review of animal and human studies. Maturitas 2016; 86:28–43.
1. Ghaffari S, Naderi Nabi F, Sugiyama MG, Lee WL. Estrogen inhibits LDL (low-density lipoprotein) transcytosis by human coronary artery endothelial cells via GPER (G-protein-coupled estrogen receptor) and SR-BI (scavenger receptor class B type 1). Arterioscler Thromb Vasc Biol 2018; 38:2283–2294.